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Age-related hearing impairment (ARHI) is the most common sensory disorder in older adults.
We conducted a genome-wide association meta-analysis of 121,934 ARHI cases and 591,699
controls from Iceland and the UK. We identified 21 novel sequence variants, of which 13 are
rare, under either additive or recessive models. Of special interest are a missense variant in
LOXHD1 (MAF= 1.96%) and a tandem duplication in FBF1 covering 4 exons (MAF= 0.22%)
associating with ARHI (OR= 3.7 for homozygotes, P= 1.7 × 10−22 and OR= 4.2 for het-
erozygotes, P= 5.7 × 10−27, respectively). We constructed an ARHI genetic risk score (GRS)
using common variants and showed that a common variant GRS can identify individuals at
risk comparable to carriers of rare high penetrance variants. Furthermore, we found that ARHI
and tinnitus share genetic causes. This study sheds a new light on the genetic architecture of
ARHI, through several rare variants in both Mendelian deafness genes and genes not pre-
viously linked to hearing.
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Hearing impairment is a common sensory defect, affecting1–2 out of every 1000 infants and over 50% of people over80 years old1,2. Around 80% of prelingual hearing loss is
caused by variants in the sequence of the genome3, most com-
monly in the GJB2 gene encoding the connexin 26 protein
involved in inner-ear homeostasis4. Over 100 genes have been
identified that cause prelingual or childhood-onset non-syn-
dromic hearing loss, and 75% of those are inherited in a recessive
manner (Hereditary Hearing Loss homepage, https://
hereditaryhearingloss.org/).
Less is known about the genetics of age-related hearing
impairment (ARHI), defined as a gradual decline of auditory
function. ARHI is one of the most common chronic conditions
affecting the elderly5 and is associated with communication dif-
ficulties and reduced quality of life6. ARHI is usually caused by
degeneration of the hair cells in the cochlea. The hair cells are
specialized receptors that detect auditory stimuli and convert
them into nerve signals that are transmitted to the brain7. ARHI
can be treated, for instance with hearing aids or cochlear implants
in severe cases. The heritability of ARHI has been estimated to be
around 50% in twin studies8. The genetics of ARHI are compli-
cated by the variability in onset, severity, and progression, as well
as the effect of environmental factors such as noise exposure that
can lead to hearing impairment9. Genome-wide association stu-
dies (GWAS) on ARHI have been performed10–16 and a recent
study based on UK Biobank self-reported hearing difficulty,
reported 44 ARHI loci17.
The standard type of hearing test is performed with an
audiometer that delivers pure tones at different frequencies
(measured in hertz (Hz)) and different intensities (measured in
decibels hearing level (dB HL)). During the test, a sound is played
at frequencies of 0.5, 1, 2, 4, 6, and 8 kHz, and each frequency at
different intensity levels. The lowest intensity of sound detection
for each individual is defined as their hearing threshold.
According to the WHO classification of hearing loss, subjects
with a hearing threshold above 25 dB HL are considered to have
hearing impairment and the higher the thresholds the greater the
impairment18 (Supplementary Table 1). Hearing thresholds at
frequencies 0.5, 1, 2, and 4 kHz were used in a pure tone average
(PTA). These frequencies represent the range of speech.
Individuals with ARHI are at increased risk of tinnitus, the
perception of a sound in the absence of an external sound. These
phantom sounds are often described as ringing, buzzing, or
hissing19. Most people experience tinnitus at some point in their
life, but for 5–15% of the general population the tinnitus is
incessant20. Treatment for tinnitus is lacking, even though 1–3%
of individuals experience severe tinnitus affecting their life sub-
stantially, including difficulty with concentration and sleep21. A
twin study estimated the heritability of tinnitus to be 56%22, yet
several genetic studies have failed to find associations of sequence
variants with tinnitus23.
To search for sequence variants associating with ARHI, we
performed a GWAS meta-analysis of 121,934 cases and 591,699
controls from two non-overlapping Icelandic datasets and the UK
Biobank (UKB). Subsequently, we assessed the effect of ARHI
associating variants on tinnitus. Fifty-one independent sequence
variants at 45 loci associate with ARHI, 41 under an additive
model and 10 under a recessive model. Twenty-one of the asso-
ciations have not been reported before, to the best of our
knowledge. Using the association results, we furthermore con-
structed a GRS for ARHI.
Results
Summary of the data and demographics of ARHI in Iceland.
We conducted a GWAS of ARHI in three datasets obtained from
the deCODE health study (DHS)24, the National Institute of
Hearing and Speech in Iceland (NIHSI) and the UKB (Fig. 1,
Supplementary Table 2).
The DHS dataset is based on audiometric measures for 11,484
Icelanders, including 4140 ARHI cases (PTA > 25 dB HL) and
7344 controls, who are part of a comprehensive phenotyping of a
general population sample enriched for carriers of rare and
potentially high impact mutations25. The subjects were between
18 and 97 years of age at the time of recruitment (43.6% men;
mean age= 55.4, standard deviation (SD)= 14.5, Supplementary
Fig. 1a). The NIHSI is a clinic where patients are referred to for
hearing and speech difficulties, and the NIHSI dataset consists of
36,905 audiometric measures of 22,212 Icelanders (55.5% men;
mean age= 48.0, SD= 32.4, Supplementary Fig. 1b), of which
43.7% were performed on children (<18 years old). The NIHSI
dataset is highly skewed toward those with ARHI, with a
prevalence among adults of 73.6% for mild (PTA > 25 dB HL),
47.1% for moderate (PTA > 40 dB HL), 13.2% for severe (PTA >
60 dB HL) and 3.1% for profound (PTA > 80 dB HL) hearing
impairment. Due to this bias, we defined the 9619 subjects with
PTA above 25 dB HL as ARHI cases and designated 298,609
Icelanders with no available hearing data as population controls
(excluding individuals in the DHS dataset). The UKB dataset
consists of 108,175 cases with self-reported hearing difficulty
and 285,746 controls of white British ancestry, at ages
ranging between 40 and 69 years (45.6% men; mean age= 56.5,
SD= 8.1).
The DHS dataset provides an opportunity to analyze the
demographics of ARHI in Iceland, although we note that some
individuals were recruited based on mutations causing or
suspected to cause hearing impairment (Supplementary Table 3).
The prevalence of hearing impairment was 36.1% for mild, 7.7%
for moderate, 1.1% for severe and 0.1% for profound impairment.
In line with previous studies26,27, the prevalence of moderate
hearing impairment at 75 years is 34% for men and 22% for
women. The audiometric measures show that hearing declines
with age at all frequencies but more drastically at the higher
frequencies of 4–8 kHz (Table 1, Supplementary Fig. 2). The
prevalence of mild hearing impairment reaches 5% shortly after
35 years and increases rapidly with age after 40; 18% at 50 years
and 40% at 60 years (Supplementary Fig. 3). Consistent with
previous reports28, women are at greater risk of ARHI at low
frequencies (0.5 and 1 kHz), while men are at more risk in the
higher frequencies (≥2 kHz) (Table 1). Previous studies have
observed an association between ARHI and short stature29–31. It
has been postulated that the association is due to low levels of
insulin-like growth factor 1 (IGF-1), which has a role in the
development of the cochlea29–31. Performing a logistic regression
on mild ARHI (>25 dB HL) against sex, age, and height, we
observe that reduced height associates with increased risk of
ARHI at the lower frequencies 0.5, 1, and 2 kHz (Table 1). After
adjusting for height, the association with increased risk of ARHI
in women at low frequencies (0.5 and 1 kHz) is no longer
significant (Table 1). This indicates that the greater risk of ARHI
at low frequencies for women is driven by the association with
reduced height. These results replicate in the NIHSI dataset
(Supplementary Table 4).
GWAS meta-analysis. To search for sequence variants associat-
ing with ARHI, we performed a meta-analysis of the three
GWASs from DHS, NIHSI, and UKB, analyzing in total 46.9
million sequence variants under both additive and recessive
models (Fig. 1). The UKB GWAS was performed on two imputed
genotype datasets, one based on variants from the Haplotype
Reference Consortium reference panel and the other based on
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variants identified through whole-exome sequencing of 50 K
study participants (see the “Methods” section). In total, 55
independent variants at 48 loci satisfied our genome-wide sig-
nificance thresholds that are dependent on sequence variant
annotation32 (“Methods”, Supplementary Table 5, Supplementary
Data 1 and 2, Supplementary Fig. 4). Because we do not restrict
the definition of ARHI cases with respect to age at measure or
severity, we might detect rare variants in the meta-analysis that
are causing prelingual or childhood-onset hearing loss instead of
ARHI. Due to this, we used the audiometric measures in the
Fig. 1 Study design and summary of results. The UKB GWAS was performed with two genotype datasets marked in red and blue. The DHS and NIHSI GWAS
was performed on one genotype dataset marked in green. WGS whole-genome sequenced, HRC Haplotype Reference Consortium, WES whole-exome
sequenced, PTA pure tone average, DHS deCODE health study, NIHSI National Institute of Hearing and Speech in Iceland, EGF expected genotype frequency.
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Icelandic datasets to estimate the predicted hearing threshold of
the carriers in childhood and observed that four of the 55 variants
cause prelingual or childhood-onset hearing loss rather than
ARHI (“Methods”, Supplementary Data 2). Two are variants in
GJB2 known to cause deafness33,34. The other two variants, only
detected in Iceland, are fully penetrant loss-of-function variants
in known Mendelian deafness genes that have not been described
before; a stop-gained variant in heterozygous state in EYA4 (p.
Tyr285Ter, MAF= 0.01%, OR= 35.6, P= 1.1 × 10−7; a
likelihood-ratio test was performed in all logistic regression
associations) and a frameshift variant in homozygous state in
OTOA (p.Ala988ArgfsTer3, MAF= 0.65%, OR= 159.60, P=
2.7 × 10−20), where all carriers have moderate to profound
hearing loss.
The UKB dataset has the largest sample size of the three
datasets and the ARHI associations for the common variants are
largely driven by the results from that dataset. Fourteen of the
ARHI variants did not associate with ARHI in the Icelandic
datasets (P > 0.05, Supplementary Data 3). However, the effects
show a consistent direction in the three datasets and the pair-wise
correlation coefficients between effect sizes are >0.56 (Supple-
mentary Fig. 5). Thirty of the associations correspond to
previously reported ARHI variants14,17,35,36. At 6 of those loci,
the previously reported variants are non-coding17, while we
identified missense or splice region variants at these loci (r2 > 0.85
between our top variant and the reported variant) (Supplemen-
tary Data 1). Thirteen of the associations not reported before, are
represented by rare variants, of which six are located in
Mendelian deafness genes and two are secondary associations at
previously reported ARHI loci (Fig. 1). Through a gene-based
burden test, where rare loss-of-function variants (MAF < 2%) in
the same gene were aggregated and tested together, we identified
one additional ARHI gene; AP1M2.
Rare variants associating with risk of ARHI. We found 16
ARHI variants that have rare genotypes with large effects
(expected genotype frequency (EGF) < 1.0%), either in the het-
erozygous state (N= 10, MAF < 0.5%) or homozygous state (N=
6, MAF < 10.0%) (Table 2, Fig. 1). In Iceland, 4.9% of the
population carries at least one of the 16 rare ARHI genotypes
with large effects, and of those carriers that are older than 55, 72%
have ARHI compared to 55% of non-carriers (DHS dataset).
Overall, carriers of rare ARHI variants have a 2.2-fold (95%
confidence interval (CI)= [1.8;2.7], P= 1.0 × 10−12) greater risk
of mild hearing impairment than the rest of the population, 3.0-
fold (CI= [2.1;4.3], P= 1.4 × 10−9) greater risk of moderate and
5.6-fold (CI= [3.1;10.2], P= 1.9 × 10−8) greater risk of severe
impairment (DHS dataset, Fig. 2a).
Five of the variants that have rare genotypes with large effects
are at loci that have not been reported for any type of hearing
impairment: FBF1, FSCN2, C10orf90, SH2D4B, and TBX2
(Supplementary Note 1).
A rare tandem duplication in FBF1, only detected in Iceland,
associates strongly with ARHI (MAFIce= 0.22%, OR= 4.2, P=
5.7 × 10−27). The variant is highly penetrant, with 81.5% of the
166 carriers having at least mild ARHI and 57.4% having
moderate to profound hearing impairment (Fig. 3a). The
duplication spans 7282 base pairs covering exons 4–7 of FBF1.
To investigate the effects of the duplication on the transcription
of the gene, we analyzed RNA sequencing data37,38 from whole-
blood of heterozygous carriers and non-carriers (N= 13,067)
(Supplementary Note 2). Out of 60 heterozygous carriers, we
found evidence of transcripts containing duplication of exons 4–7
defined by an extra splicing between exon 7 and 4 (Fig. 3b). This






































































































































































































































































































































































































































































































































































































































































































































































ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02224-9
4 COMMUNICATIONS BIOLOGY |           (2021) 4:706 | https://doi.org/10.1038/s42003-021-02224-9 | www.nature.com/commsbio
of the 13,007 non-carriers. We estimate that transcripts with
splicing between exon 4 and 7 represent 7.5% (CI= [5.7;9.2]) of
FBF1 transcripts in carriers. Three other variants are correlated
(r2 > 0.8) with the duplication but none of them are coding
(Supplementary Fig. 6a).
Six of the variants not reported before, with rare genotypes and
large effects on ARHI, are coding variants located in Mendelian
deafness genes: LOXHD1, MPZL2, SLC411, SLC26A5, TBC1D24,
and TMPRSS3. Rare variants in these genes have been reported to
cause severe to profound hearing impairment described as either
prelingual or childhood-onset (DFNB77, DFNB111, DFNB61,
DFNA65, DFNB86, and DFNB8; OMIM #613079, #618145,
#217400, #613865, #616044, #614617, and #601072). However,
apart from TMPRSS3, the ARHI associations we find in these
genes are with missense variants that have milder effect than the
prelingual or childhood-onset variants (Supplementary Note 3,
Table 2, Fig. 4a–d).
The missense variant in LOXHD1, p.Arg1090Gln, on chromo-
some 18q21.1, associates with increased risk of ARHI under the
recessive model (OR= 3.92, P= 8.9 × 10−22). P.Arg1090Gln has
a MAF of 2.96% in Iceland and 1.99% in the UK and reaches
genome-wide significance in both Iceland and the UK (Supple-
mentary Data 1). No other variants are correlated with p.
Arg1090Gln (r2 < 0.4, Supplementary Fig. 6b). The variant has
high penetrance, with 82.3% of the 62 homozygotes in the
Icelandic datasets having ARHI and 48.4% having moderate to
profound hearing impairment (Fig. 4a). We had information on
hearing aid usage and the age when hearing aid usage started for
8211 of the 11,484 individuals in the DHS dataset and found that
15 out of 37 homozygous carriers use hearing aids and started
using them earlier (mean age= 46.3 years, SD= 15.7) than
heterozygotes and non-carriers (mean age= 60.0 years, SD=
14.8, P= 0.031; t-test). Heterozygotes are also at increased risk of
ARHI (OR= 1.07, P= 2.0 × 10−4). However, this risk is much
lower than the risk of homozygotes and therefore the effect of this
variant deviates from the additive model (P= 3.3 × 10−12,
Supplementary Data 4).
A rare frameshift variant, c.208delC, in TMPRSS3 associates
with ARHI under the additive model (OR= 1.49, P= 8.3 × 10−8,
MAFIce= 0.22%, MAFUK= 0.07%). In the homozygous state,
c.208delC has been reported to cause congenital deafness (OMIM
# 601072), but the increased risk of ARHI of heterozygous
carriers has not been reported. In the Icelandic datasets, the only
homozygous carrier has profound hearing loss. In the hetero-
zygous state, the variant shows variable expressivity (Fig. 4e);
where some carriers have normal hearing, 52 carriers have
moderate, 17 have severe and 4 have profound hearing loss.
Battelino et al. reported a Slovenian family-trio with congenital
profound hearing loss, where the mother and the son were
homozygous carriers of c.208delC and the father was a
heterozygous carrier of c.208delC in TMPRSS3 and c.35delG in
GJB239. Our results suggest that one copy of c.208delC in
TMPRSS3 can cause profound hearing loss.
An ARHI gene detected with a burden test. Using a loss-of-
function variant gene-based burden test, the gene AP1M2, on
chromosome 19p13.2, associates with ARHI under the recessive
model in the Icelandic datasets (OR= 28.9, P= 4.6 × 10−7).
Twelve homozygotes or compound-heterozygotes for loss-of-
function variants with MAF < 2% in AP1M2 had been invited to
participate in the deCODE health study. Nine of them partici-
pated, three homozygous carriers of a stop-gained variant,
p.Arg386Ter (MAF= 0.22%), three homozygous carriers for a
splice donor variant, c.673+ 2T>C (MAF= 0.37%), and three
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additional compound-heterozygous carrier had audiometric
measures from the NIHSI. Four of the individuals have severe,
two have moderate and two have mild ARHI. Five of them
reported the use of hearing aids, and their average age when
starting using hearing aids (mean= 27.8, SD= 14.9) is sub-
stantially younger than that of other hearing aid users (mean=
60.2, SD= 15.1, P= 0.022; t-test). RNA and protein expression
analyses of inner-ear tissue40–42 have shown that Ap1m2 is
expressed 7-fold higher in hair cells than in non-hair cells in mice
with a false discovery rate of 3.4 × 10−3, suggesting a specific role
in hair cell function (Supplementary Table 6). Non-syndromic
hearing loss has been linked to chromosome 19p13.2 in families
from Pakistan43 and Germany44, without a specific gene being
implicated.
The effect of the variants on ARHI by genotype. It is interesting
that 19% of the variants associate with ARHI under the recessive
model, a much higher fraction than other age-related diseases. To
further explore the effect of all of the ARHI associating variants
per genotype we tested them under the genotypic model esti-
mating the effect of heterozygous and homozygous carriers
separately (Supplementary Data 4). We found that p.Arg402Gln
in TYR, p.Val504Met in KLHDC7B, p.Thr656Met in SYNJ2, and
p.Leu113Val in CLRN2 have stronger effects on homozygotes
than expected under the additive model (P < 0.05). Furthermore,
we found that the variants in ILDR1, CHMP4C, and CCDC68,
reported before as additive17, are better explained by the recessive
model, only showing significant effects on homozygous carriers
(Supplementary Data 4).
Dimensions of the audiometric data. In the Icelandic datasets,
the subjects underwent an audiometric test providing more
information about the severity of the ARHI and the affected
frequencies than in the UKB dataset. To further explore which
hearing frequencies are affected by the ARHI variants, we tested
each frequency (0.5, 1, 2, 4, 6, and 8 kHz) separately for asso-
ciation with the ARHI variants (Supplementary Data 3, Fig. 5).
Most of the ARHI variants have similar effects at all frequencies
although some variants have stronger effects on lower frequencies
(Fig. 5b) and others on higher frequencies (Fig. 5a). For instance,
p.Arg1090Gln in LOXHD1 affects the lower frequencies more
than higher frequencies under a recessive model, with the greatest
effect on 1 kHz (OR= 8.4, P= 1.6 × 10−18), which is different
from its effect on ARHI at 6 and 8 kHz (Phet < 0.02; Q-test).
Furthermore, six ARHI variants, that do not associate with PTA-
based ARHI in Iceland (P > 0.05), associate nominally with ARHI
for some particular frequency (Supplementary Data 3, Fig. 5).
Association of ARHI variants with tinnitus. We tested the
ARHI variants for association with tinnitus using self-reported
information from DHS and UKB (Ncases= 47,657, Ncontrols=
111,607, Supplementary Table 7). ARHI variants detected under
the additive model were tested for tinnitus using the additive
model and ARHI variants detected under the recessive model
were tested for tinnitus using the recessive model. Thirteen ARHI
variants associate with tinnitus, controlling the false discovery
rate at 0.05 using the Benjamini–Hochberg procedure (Fig. 6a;
variants with lower OR shown in detail in Fig. 6b; Supplementary
Fig. 2 ARHI risk for rare variants and a common variant GRS. a The
fraction of individuals with mild (gray), moderate (orange), and severe
(red) hearing impairment in the DHS dataset (N= 11,484) among the 4.9%
of subjects that are carriers of any of the 16 rare ARHI variants (dots) and
the 95.1% that are not carriers (squares), shown for different age groups.
The corresponding dashed lines are polynomial regression lines of best fit.
b The risk of ARHI for each GRS decile compared to the bottom decile
expressed in ORs. The ORs from the DHS dataset (4140 cases and 7344
controls) are represented with red dots and the ORs from the NIHSI dataset
(9619 cases and 298,609 controls) are represented with purple dots. The
gray lines represent 95% confidence intervals. The dashed line is the
reference for the bottom GRS decile (OR= 1). c The fraction of individuals
with ARHI among subjects in the DHS dataset (N= 11,484) in the bottom
GRS decile in blue and the top GRS decile in red, shown for different age
groups. The corresponding dashed lines are regression lines of best fit.
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Table 7). Variants in CTBP2, CRIP3, AGO2, PHLDB1, LMX1A,
SLC26A5, ACADVL, SYNJ2, and CLRN2 associated with tinnitus
under the additive model and variants in ILDR1, ABCC10,
SH2D4B, and C10orf90 associated with tinnitus under the
recessive model. For all of the thirteen variants, the ARHI risk-
increasing allele increases the risk of tinnitus, and the effect of all
the ARHI variants on ARHI risk and tinnitus risk are highly
correlated (r= 0.72, P= 6.2 × 10−8 and r= 0.86, P= 6.0 × 10−4
for the additive and recessive model, respectively; t-test, Fig. 6).
Genetic risk score predicts ARHI risk. We constructed a genetic
risk score (GRS) for ARHI, based on the 35 ARHI variants with
EGF > 1%, using effect sizes from the UKB dataset. The GRS
associates with ARHI in both Icelandic datasets (OR= 1.31, CI=
[1.25;1.37], P= 4.1 × 10−29 and OR= 1.18, CI= [1.15;1.21], P=
7.5 × 10−39 in DHS and NIHSI datasets, respectively) and the
association is dose-dependent over GRS deciles (Fig. 2b). In the
DHS dataset, individuals in the top decile of the GRS have 2.5-
fold (CI= [2.0;3.1], P= 6.1 × 10−18) greater risk of ARHI than
those in the bottom decile. Comparing the cumulative risk of
ARHI against age between the top and bottom GRS deciles, shows
that individuals in the bottom decile have their ARHI 10 years
later than those in the top decile (Fig. 2c). Furthermore, indivi-
duals in the top GRS decile have a 3.2-fold (CI= [2.1;4.8], P=
2.1 × 10−8) and 2.7-fold (CI= [1.1;6.7], P= 0.031) greater risk of
moderate and severe hearing impairment, respectively, than those
in the bottom decile. If we compare the 4.9% who carry any of the
16 rare ARHI variants to the bottom 10% of the GRS, the ORs are
3.4 for mild, 6.1 for moderate, and 9.2 for severe hearing
impairment (P= 3.0 × 10−19, 8.4 × 10−13 and 1.0 × 10−7,
respectively). Therefore, relative to the bottom GRS decile, the
ARHI OR for carriers of rare variants is larger than the ARHI OR
for individuals in the top GRS decile, but the ORs do not show
significant heterogeneity (Phet= 0.075; Q-test). However, the risk
of moderate and severe ARHI for carriers of rare variants is
substantially greater than the risk for the top GRS decile (Phet <
0.05; Q-test).
As we have described, the severity of the hearing impairment
for carriers of the highly penetrant variants in LOXHD1 and FBF1
varies from mild to profound. We hypothesize that the GRS could
act as a modifier on the expressivity, i.e., that some of the variable
expressivity of these highly penetrant variants could be explained
by the common variants associating with ARHI. We estimated
the relationship between these variants and the GRS on the PTA
hearing thresholds and found positive interaction for both
LOXHD1 and FBF1 (P= 6.8 × 10−4 and P= 4.7 × 10−3, respec-
tively; likelihood-ratio test). This shows that among carriers of
these highly penetrant genotypes, those who additionally have a
high GRS are at a greater risk of a more severe ARHI than those
that have a low GRS.
Long-term exposure to occupational loud noises is a risk factor for
ARHI9,45. We had information on the occupation the subjects had
for the majority of their lives for 7642 of the 11,484 individual in the
DHS dataset. Three occupational categories associated with increased
risk of ARHI; plant and machine operators and assemblers (N= 508,
OR= 1.88, CI= [1.49;2.37], P= 8.4 × 10−8), craft and related trades
workers (N= 1,172, OR= 1.56, CI= [1.32;1.84], P= 1.3 × 10−7)
and agricultural and fishery workers (N= 783, OR= 1.55, CI=
[1.30;1.85], P= 1.6 × 10−6). We tested for an interaction effect
between long-term occupational noise exposure and the ARHI GRS
on the risk of ARHI but did not find a significant interaction (P=
0.94; likelihood-ratio test). Among the individuals in the top GRS
decile, noise exposure associates with increased risk of ARHI (OR=
1.77, CI= [1.18;2.67], P= 6.3 × 10−3) similar to the rest of the
population (OR= 1.70, CI= [1.47;1.97], P= 1.2 × 10−12, Phet= 0.86;
Q-test).
Discussion
In what we believe is the largest GWAS meta-analysis on ARHI to
date, we found an association with 51 variants, of which 21 have
not been reported before, using audiometric measurements from
Icelanders and data on self-reported hearing difficulty from the
UKB. This study yielded a larger number of rare variants, both
under additive and recessive models, than previous GWAS stu-
dies that reported common variant associations with small to
moderate effects on ARHI. These findings include variants in
both known Mendelian deafness genes and genes not previously
linked to hearing.
We constructed an ARHI GRS and found that individuals in
the top GRS decile are at 2.5-fold greater risk than those in the
bottom decile, and on average, they develop ARHI 10 years earlier
than the bottom decile. The 2.5-fold greater risk is comparable to
the 3.4-fold greater risk of carriers of rare ARHI variants than
those in the bottom GRS decile. However, carriers of rare ARHI
Fig. 3 A tandem duplication in FBF1 associates with ARHI. a) The PTA hearing threshold of the heterozygous carriers (N=166) of the tandem duplication
in FBF1 in DHS and NIHSI datasets are indicated by yellow squares and the average PTA hearing thresholds of non-carriers in the DHS dataset (N= 11,484)
are represented with gray dots. The corresponding dashed lines are polynomial regression lines of best fit. The gray vertical lines represent 95% confidence
intervals. b) The exon structure of the wild type and the tandem duplication variant in transcript ENST00000586717.5 of FBF1 on the reverse strand of
chromosome 17. The exons of the transcripts are numbered, and solid black lines represent splicing between exons. The tandem duplication creates a
longer transcript with extra sets of exons 4–7 that leads to novel splice junction starting at the end of exon 7 and splicing into the beginning of exon 4. The
adjacent sequences of the exons are shown, and together they form the 32 bp sequence used for identification of the novel junction.
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variants have substantially greater risk of moderate and severe
ARHI than individuals in the top GRS decile, showing that the
rare variants identified in this study predispose to more severe
ARHI than the combination of common variants in the GRS.
Despite the importance of hearing in everyday life, ARHI is
often not recognized by patients and left untreated; only 22% of
people with mild hearing impairment report a hearing
handicap6. Because of this, ARHI is often not diagnosed until
Fig. 4 Changes in PTA hearing thresholds by age for carriers of rare ARHI variants in Mendelian deafness genes. Effects of variants in a LOXHD1,
bMPZL2, c SLC4A11, d SLC26A5, and e TMPRSS3 are shown. In a and b, the average PTA in the DHS dataset are represented with gray dots for non-carriers
and orange dots for heterozygotes and the PTA hearing thresholds of the homozygous carriers in DHS and NIHSI datasets are represented with red
squares. In c, d, and e, the average PTA of non-carriers in the DHS dataset are represented with gray dots and the PTA hearing threshold of the
heterozygous carriers in DHS and NIHSI datasets by yellow squares. The dashed red lines are linear regression lines of best fit and the dashed yellow and
grey lines are polynomial regression lines of best fit. The gray vertical lines represent 95% confidence intervals. A figure for TBC1D24 is not included
because the variant was detected in UKB dataset only and therefore audiometric measures are not available for the carriers.
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several years after onset and has then often already had many
negative consequences such as effects on employment, social
isolation, and depression46. Due to this, there is a need for
better screening strategies, and using a GRS to stratify indivi-
duals into risk groups could enable enhanced screening. Iden-
tifying high-risk individuals might also help with preventing or
reducing the severity of the hearing impairment. We have
shown that noise exposure increases the risk of ARHI among
those who are already at high genetic risk. It shows that
avoiding loud noises is even more important for those who have
a genetic predisposition to ARHI.
Previous reports have claimed that over 70% of non-syndromic
prelingual hearing loss is inherited in a recessive manner47. In
this study, we found six variants that associate with ARHI under a
recessive mode of inheritance. For instance, the variant in
LOXHD1 is genome-wide significant in the UKB data alone, but
was not detected by Wells et al. with the same dataset under an
additive model17. In addition, we show that three variants pre-
viously reported to associate with ARHI under an additive model
are truly recessive and four variants detected under an additive
model in this study have stronger effects on homozygous carriers
than expected under an additive model. These results highlight
the importance of applying a recessive model when searching for
variants associating with ARHI, which has not been done in
previous GWASs.
A limitation of this work is that in the three datasets, the ARHI
phenotype is defined in different ways. Because we did not restrict
the definition of ARHI in terms of age of onset or severity, we
performed follow-up analysis for all rare variants to make sure
that the reported variants really associate with ARHI and not
prelingual or childhood-onset deafness. Our results for common
variants were mainly driven by the UKB dataset but 38 out of 51
variants replicated in the combined Icelandic datasets. The lack of
replication in the DHS dataset is most likely due to smaller
sample size, while in the NIHSI dataset it might be due to dif-
ferences in the phenotype ascertainment, where patients are
referred to NIHSI for hearing problems. Using population con-
trols in the NIHSI dataset that have not been specifically screened
for hearing impairment, will also misclassify some cases as con-
trols. However, the effect sizes from the UK are highly correlated
with effect sizes from Iceland and have consistent direction of
effects. The age of onset, severity, and progression of ARHI are
highly variable between individuals, and future GWAS could
further analyze subtypes of ARHI. The Icelandic datasets provide
more details regarding these factors as well as the measures of
hearing at specific frequencies. Some ARHI variants have stronger
effects on particular frequencies, while most affect all frequencies
similarly.
We found six loci that have not been reported to affect hearing
in humans before; FBF1, FSCN2, TBX2, C10orf90, SH2D4B, and
AP1M2. Inner-ear protein expression analysis in mice40 have
shown that the mouse homologs Fscn2, Tbx2, C10orf90, Sh2d4b,
and Ap1m2 have higher expression, ranging from 5 to 43-fold, in
hair cells versus non-hair cells (Supplementary Table 6), sug-
gesting that these genes have specialized roles in the inner-ear
hair cells, but degeneration of the inner-ear hair cells is the main
cause of ARHI5.
The two strongest associations not reported before, were with
the highly penetrant tandem duplication covering exons 4–7 in
FBF1, detected under an additive model, and a missense variant
in LOXHD1, affecting ARHI in homozygous state. FBF1 encodes
Fas-binding factor 1, a keratin-binding protein necessary for
ciliogenesis48,49. We speculate that FBF1 may have a role in the
cilia of the inner ear, but further studies are needed to determine
the biological effect of the duplication and the mechanism behind
the association of FBF1 with ARHI. LOXHD1 encodes lipox-
ygenase homology domain 1, which consists of 15 PLAT (poly-
cystin‐1, lipoxygenase, alpha‐toxin) domains50. Grillet et al.
showed that LOXHD1 is expressed in the functionally mature
mechanosensory hair cells in the inner-ear and loss-of-function
mutations in the gene lead to auditory defects in mice and
humans, indicating an essential role for normal hair cell
function50. Homozygous carriers of p.Arg1090Gln in LOXHD1
report a younger age for hearing aid usage than the rest of hearing
aid users, showing that the variant is associated with a severe
form of ARHI. Given the frequency of p.Arg1090Gln (gnomAD,
https://gnomad.broadinstitute.org/), we estimate the number of
Fig. 5 Effects of the ARHI variants on ARHI per frequency. Each row
shows the effect, the logarithm of the estimated odds ratios, of the minor
allele on ARHI for PTA, the average of 0.5, 1, 2, and 4 kHz, and separately
for each frequency, 0.5, 1, 2, 4, 6, and 8 kHz, for a common variants with
EGF > 1% and b rare variants with EGF < 1%. The effect is shown only for
associations with P-value <0.05. Red color represents an increased risk of
ARHI and blue color represents decreased risk.
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homozygous carriers to be around 300 in Iceland, 24,000 in the
UK, and 300,000 in the whole of Europe.
We also tested the ARHI variants for association with tinnitus.
Tinnitus is considered to have a broad etiology and can be caused by
problems in the entire auditory pathway51. ARHI and tinnitus are
correlated phenotypes, but shared genetic causes have not been
broadly explored. We found that 13 of the 51 ARHI variants also
associated with tinnitus, showing that some pathogenic processes that
cause ARHI also increase the risk of tinnitus.
Our knowledge of the pathogenesis of ARHI is still limited, but
the work presented here reveals several loci, shedding a light on
the genetics underlying this common sensory defect.
Methods
Phenotype datasets. For the meta-analysis, we conducted a GWAS of ARHI in
three datasets under both additive and recessive models.
The DHS dataset. Pure tone audiometric air conduction testing was performed for
11,484 Icelanders as a part of a comprehensive phenotyping of a general population
sample enriched for carriers of rare and potentially high impact mutations25 (the
deCODE health study24). Homozygous carriers of p.Arg1090Gln in LOXHD1 were
recruited, resulting in 37 carriers that participated (Supplementary Table 3). For
the GWAS, 4140 individuals with PTA > 25 were defined as ARHI cases and the
remaining 7344 as controls. Participation in the deCODE health study includes
blood sample collection, numerous physical measurements, permission to access a
wide range of health-related information including hospital data, a verbal inter-
view, and an online questionnaire about health and lifestyle, including questions on
hearing aid usage and tinnitus. All participants of the study gave written informed
consent, in accordance with the Declaration of Helsinki, and the study was
approved by the Icelandic Data Protection Authority and the National Bioethics
Committee (VSNb2015120006/03.01 with amendments).
The NIHSI dataset. Pure tone audiometric air conduction testing was performed
for 22,212 Icelanders at the National Institute of Hearing and Speech in Iceland
(NIHSI). For the GWAS, 9619 individuals were defined as ARHI cases (PTA > 25)
and 298,609 individuals were selected as population controls (excluding individuals
in the DHS dataset). All participants who donated samples gave informed consent
and the study was approved by the Icelandic Data Protection Authority and
National Bioethics Committee (VSN-18-186).
The UKB dataset. The UKB study is a large prospective cohort study of around
500,000 individuals from the UK52. Extensive phenotypic and genotypic infor-
mation has been collected for the participants, including self-reported hearing
difficulty and tinnitus. For the GWAS, we defined 108,175 ARHI cases as those
who answered “Yes” or “I am completely deaf” to the question “Do you have any
difficulty with your hearing?” and 285,746 controls as those who answered “No”. In
our analysis, we only included individuals determined to be of white British
ancestry53 and we use LD score regression54 to account for inflation in test statistics
due to relatedness. All participants of the UK Biobank study gave informed consent
and the study was approved by the North West Research Ethics Committee (REC
Reference Number: 06/MRE08/65).
Audiometric test. In DHS and NIHSI datasets, the pure tone air conduction
audiometric test was performed by specially trained staff. The audiometer delivers
pure tones at 0.5, 1, 2, 4, 6, and 8 kHz at different intensity levels, usually starting at
20 dB HL and increased if necessary. For each individual and each ear, the lowest
intensity of sound detection is defined as their hearing threshold at that frequency.
The pure tone average (PTA) was defined as the average hearing threshold at 0.5, 1,
2, and 4 kHz (according to the classification of the WHO). We define ARHI cases
as those with PTA > 25.
Genotype datasets. In the Icelandic GWASs, using the DHS and NIHSI datasets,
we analyzed high-quality 34.0 million sequence variants identified through whole-
genome sequencing of 49,708 Icelanders which have been described in detail55,56.
In summary, we whole-genome sequenced the Icelanders using Illumina technol-
ogy to a mean depth of at least 17.8× and median depth of 36.9×. The sequence
variants were jointly called using Graphtyper57, thereof 79.318 high-confidence
structural variants described previously58. We genotyped 166,281 Icelanders using
Illumina SNP chips and their genotypes were phased using long-range phasing59.
Genotypes of the 34.0 million sequence variants were imputed into all chip-typed
Icelanders as well as relatives of the chip-typed, to increase the sample size for
association analysis. All tested variants had imputation information over 0.8.
The UKB GWAS was performed with two sets of genotypes. The primary
analysis was performed with 26.5 million high-quality variants (imputation info >
0.8) from the Haplotype Reference Consortium (HRC) reference panel, imputed
into chip-typed individuals of European ancestry53. The genotyping was performed
using a custom-made Affimetrix chip, UK BiLEVE Axiom in the first 50,000
individuals60, and with Affimetrix UK Biobank Axiom array in the remaining
participants61. Imputation was carried out by Wellcome Trust Centre for Human
Genetics using a combination of 1000Genomes phase 362, UK10K63, and HRC
reference panels64, for up to 93 million variants53. In addition, we performed a
GWAS with 922 thousand variants identified through whole-exome sequencing of
49,960 study participants65, imputed into chip-typed individuals of European
ancestry.
Statistics and reproducibility. Logistic regression was used to test for the association
between sequence variants and binary traits. For the additive model, the expected allele
counts were used as a covariate while for the recessive model, the product of the
maternal and paternal genotype probabilities was used as a covariate. For the genotypic
model, separate parameters were included for heterozygotes and homozygotes. Other
available individual characteristics that correlate with the trait were additionally
Fig. 6 Effect of the ARHI variants on tinnitus. The effect of the ARHI variants on ARHI is plotted against their effect on tinnitus for a all ARHI variants and
b zoomed-in on variants from (a) with ARHI OR < 1.35. Effects are shown as the logarithm of the estimated odds ratios. ARHI variants detected under the
additive model were tested for tinnitus using the additive model (blue dots) and ARHI variants detected under the recessive model were tested for tinnitus
using the recessive model (red dots). The corresponding dashed lines represent results from a linear regression using MAF(1-MAF) as weights. Variants
that affect tinnitus, controlling the false discovery rate at 0.05, are plotted with darker color and labeled with their corresponding gene. All effects are
shown for the ARHI risk-increasing allele. Error bars represent 95% confidence intervals. The dotted lines represent results from a weighted linear
regression using MAF(1-MAF) as weights, red for recessive variants and blue for additive, and the weighted correlation coefficients (r) and the
corresponding P-values are shown in (a).
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included in the model. In the DHS and NIHSI datasets, those were sex, county of birth,
current age or age at death (including first and second-order terms), blood sample
availability, and an indicator function for the overlap of the lifetime of the individual
with the time span of phenotype collection. In the UKB dataset, those were sex, age, and
40 principal components in order to adjust for population stratification.
We used LD score regression to account for distribution inflation in the dataset
due to cryptic relatedness and population stratification54. Using 1.1 million
variants, we regressed the χ2 statistics from our GWASs against LD score and used
the intercepts as a correction factor. The estimated correction factors for ARHI
were 1.05, 1.20, and 1.05 in DHS, NIHSI, and UKB datasets, respectively.
Because the UKB GWAS was performed on two sets of genotypes, we
performed two separate meta-analyses. Both meta-analyses combined results from
three GWAS using DHS, NIHSI, and UKB datasets. In meta-analysis I, we used the
UKB GWAS results based on the variants from the HRC reference panel and in
meta-analysis II we used the UKB GWAS results based on the variants identified
through whole-exome sequencing. When meta-analyzing the three GWASs, we
used a fixed-effects inverse variance method66 which is based on effect estimates
and standard errors from all datasets. Sequence variants from Iceland and the UKB
were matched on position and alleles.
For the genotypic model P-values were computed by comparing the genotypic
model to the null model, using a likelihood-ratio test. For the genotypic model
meta-analysis, sample size approach was used based on P-values and sample size67.
A Q-test68 was used to test for heterogeneity between effect sizes.
Definition of ARHI variants. The PTA-based definition of ARHI used in the Ice-
landic datasets does not exclude individuals that are completely deaf or have childhood-
onset hearing loss. The GWAS can therefore detect rare associating variants that cause
prelingual or childhood-onset hearing loss instead of ARHI. Due to this, for all the rare
variants that satisfied the genome-wide significance thresholds, we fit a linear regression
model, with the PTA hearing threshold of the carriers as response and age as covariate,
to estimate the predicted PTA hearing threshold of the carriers in childhood. Variants
that had predicted hearing threshold of 25 dB HL at 10 years of age were considered to
be causing childhood-onset hearing loss.
Significance thresholds. The genome-wide significance thresholds were corrected for
multiple testing with a weighted Bonferroni adjustment32. The weights, based on
enrichment of variant classes with predicted functional impact among association
signals, were estimated from the Icelandic data, resulting in significance thresholds of
2.4 × 10−7 for loss-of-function variants, 4.9 × 10−8 for moderate-impact variants, 4.4 ×
10−9 for low-impact variants, 2.2 × 10−9 for other variants within DHS sites and 7.4 ×
10−10 for remaining variants.
We evaluated false discovery rate, assessed with the q-value package in R. The
P-value cutoff of 5.0 × 10−8 corresponded to q-values of 0.0013 for the additive
model and 0.0025 for the recessive model, which add up to 0.4%.
In the burden test, a genome-wide significance threshold of 0.05/18,482= 2.7 ×
10−6 was used, correcting for the number of autosomal protein-coding RefSeq
genes69,70.
Conditional analysis. To search for secondary association signals at each locus, we
applied a stepwise conditional analysis, adding the top variant as a covariate when
testing all other variants in a 1 Mb window around the top variant. We used a
Bonferroni-adjusted significance threshold for secondary associations. We found
independent secondary associations at 6 loci.
Genetic risk score. The GRS for ARHI was constructed using the 35 detected
variants with EGF > 1% and estimated effects from the UKB dataset. If we let mvi
and pvi be the genotype probability for individual i and sequence variant v at the













where β are the effects of the n variants detected with the additive model and γ are
the effects of the m variants detected with the recessive model.
Correlation between effect sizes. When assessing the relationship between effect
sizes, we fitted a weighted linear regression model where each variant was weighted
by f 1 f  where f is the minor allele frequency of the variants.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the article, in supplementary files, and upon request. The sequence variants from
the Icelandic population whole-genome sequence data have been deposited at the
European Variant Archive under accession PRJEB15197. GWAS summary statistics will
be made available at http://www.decode.com/summarydata.
Code availability
We used the following publicly available software for the whole-genome sequencing
process: BWA 0.7.10 mem (https://github.com/lh3/bwa), Picard tools 1.117 (https://
broadinstitute.github.io/picard/), SAMtools 1.3 (http://samtools.github.io/), Bedtools
v2.25.0-76-g5e7c696z (https://github.com/arq5x/bedtools2/), GraphTyper 1.3 (https://
github.com/DecodeGenetics/graphtyper), Variant Effect Predictor (https://github.com/
Ensembl/ensembl-vep).
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